High versus standard adalimumab induction dosing regimens in patients with moderately to severely active ulcerative colitis: results from the SERENE-UC induction study

(1) Hospital Clinic de Barcelona,Barcelona,Spain

(2) Icahn School of Medicine at Mount Sinai,New York,United States

(3) AMC Amsterdam Inflammatory Bowel Disease Centre - Academic Medical Center, AMC Amsterdam Inflammator,Amsterdam,Netherlands

(4) University Hospital Schleswig-Holstein,Kiel,Germany

(5) University of Calgary,Calgary,Canada

(6) Nancy University Hospital Inserm U954 Dept. of Hepato-Gastroenterology,Vandoeuvre les Nancy,France

(7) Mayo Clinic,Rochester,United States

(8) Istituto Clinico Humanitas ( Rozzano ),Milan,Italy

(9) Univeristy Hospital CHU of Liege,Liege,Belgium

(10) Fondazione A. Gemelli Hospital IRCCS,Rome,Italy

(11) University Hospitals Leuven, KU Leuven,Leuven,Belgium

(12) Medical University of Vienna,Vienna,Austria

(13) AbbVie Inc.,Chicago,United States

(14) AbbVie,North Chicago,United States

(15) AbbVie Inc,North Chicago,United States

(16) AbbVie Deutschland GmbH & Co KG Abt. Immunologie,Ludwigshafen,Germany

(17) University of California,San Diego,United States



This item was part of the Paradigm shifts in IBD treatment session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019